PureTech Health, the Boston-based clinical-stage biotherapeutics company, has announced the spin-out of its new entity, Celea, which has successfully secured $180 million (approximately £140 million) in financing. This substantial investment is earmarked to accelerate the development of a novel therapeutic designed to treat Idiopathic Pulmonary Fibrosis (IPF), a severe and progressive lung disease.
The creation of Celea as a standalone company underscores PureTech's strategy of incubating and then independently financing promising drug candidates. IPF is a chronic condition characterised by the progressive scarring of the lungs, leading to breathlessness and a significant decline in lung function. Current treatments for IPF aim to slow the progression of the disease, but there is no cure, and the median survival time after diagnosis is typically three to five years.
The newly secured funding for Celea is expected to propel the drug through crucial clinical trial phases. This investment highlights the urgent need for more effective treatments for IPF, a condition that affects thousands of individuals across the UK. According to the British Lung Foundation, an estimated 32,500 people in the UK are living with IPF, with approximately 5,000 new diagnoses each year.
The development of new therapies is critical, as existing treatments, such as pirfenidone and nintedanib, can slow disease progression but often come with significant side effects and do not halt the disease entirely. A novel drug with a different mechanism of action could offer a much-needed alternative or complementary therapy, potentially improving the quality of life and extending the lifespan for those afflicted by this devastating illness.
This spin-out and financing round represent a significant step forward in the biotech sector's efforts to address high unmet medical needs. The capital infusion will allow Celea to focus exclusively on its IPF programme, bringing specialised resources and expertise to bear on the complex challenges of developing a new lung disease treatment.